InfuSystem (NYSEAMERICAN:INFU) Downgraded to Buy at StockNews.com

StockNews.com cut shares of InfuSystem (NYSEAMERICAN:INFU) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday.

Separately, Lake Street Capital raised InfuSystem to a strong-buy rating in a report on Thursday, May 9th.

InfuSystem Stock Performance

InfuSystem stock opened at $6.63 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.51 and a current ratio of 1.87. The stock has a market cap of $141.22 million, a P/E ratio of -663,000.00 and a beta of 1.44. InfuSystem has a fifty-two week low of $5.74 and a fifty-two week high of $10.99.

InfuSystem (NYSEAMERICAN:INFU) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $33.70 million for the quarter. InfuSystem had a net margin of 0.07% and a return on equity of 0.16%.

Hedge Funds Weigh In On InfuSystem

Several institutional investors and hedge funds have recently made changes to their positions in INFU. Vanguard Group Inc. grew its position in InfuSystem by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 1,083,730 shares of the medical instruments supplier’s stock worth $9,288,000 after acquiring an additional 18,432 shares during the last quarter. Wasatch Advisors LP increased its stake in shares of InfuSystem by 3.4% in the fourth quarter. Wasatch Advisors LP now owns 846,609 shares of the medical instruments supplier’s stock worth $8,923,000 after buying an additional 27,881 shares during the period. Ranger Investment Management L.P. raised its holdings in InfuSystem by 4.7% during the 4th quarter. Ranger Investment Management L.P. now owns 689,842 shares of the medical instruments supplier’s stock valued at $7,271,000 after buying an additional 30,835 shares during the last quarter. First Eagle Investment Management LLC boosted its position in InfuSystem by 10.0% during the 2nd quarter. First Eagle Investment Management LLC now owns 666,048 shares of the medical instruments supplier’s stock valued at $4,549,000 after buying an additional 60,813 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in InfuSystem by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the medical instruments supplier’s stock worth $641,000 after acquiring an additional 5,391 shares during the last quarter. Institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.